MX385357B - Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma - Google Patents

Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma

Info

Publication number
MX385357B
MX385357B MX2017014621A MX2017014621A MX385357B MX 385357 B MX385357 B MX 385357B MX 2017014621 A MX2017014621 A MX 2017014621A MX 2017014621 A MX2017014621 A MX 2017014621A MX 385357 B MX385357 B MX 385357B
Authority
MX
Mexico
Prior art keywords
compounds
modulators
substituted tetrahydroquinolinone
ror gamma
substituted
Prior art date
Application number
MX2017014621A
Other languages
English (en)
Other versions
MX2017014621A (es
Inventor
Chetan Pandit
Ujjinamatada Ravi Kotrabasaiah
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MX2017014621A publication Critical patent/MX2017014621A/es
Publication of MX385357B publication Critical patent/MX385357B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona tetrahidroquinolinona sustituida y compuestos relacionados de la fórmula (I), que son terapéuticamente útiles como moduladores de receptores huérfanos (ROR) relacionados con receptores de ácido retinoico, más particularmente como moduladores de ROR?. Estos compuestos son útiles en el tratamiento y la prevención de enfermedades y / o trastornos, en particular su uso en enfermedades y / o trastornos mediados por el receptor ROR?. La presente invención también proporciona la preparación de los compuestos y formulaciones farmacéuticas que comprenden al menos una de las tetrahidroquinolinonas sustituidas o compuestos relacionados de la fórmula (I), junto con un vehículo, diluyente o excipiente farmacéuticamente aceptable para la misma.
MX2017014621A 2015-05-15 2016-05-13 Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma MX385357B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2448CH2015 2015-05-15
PCT/IB2016/052773 WO2016185342A1 (en) 2015-05-15 2016-05-13 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Publications (2)

Publication Number Publication Date
MX2017014621A MX2017014621A (es) 2018-06-28
MX385357B true MX385357B (es) 2025-03-18

Family

ID=57319522

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009561A MX394388B (es) 2015-05-15 2016-05-13 Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
MX2017014621A MX385357B (es) 2015-05-15 2016-05-13 Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021009561A MX394388B (es) 2015-05-15 2016-05-13 Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma

Country Status (26)

Country Link
US (4) US20180200247A1 (es)
EP (2) EP3845526A1 (es)
JP (2) JP6684516B2 (es)
KR (1) KR102702236B1 (es)
CN (2) CN108026045B (es)
AU (2) AU2016262969C1 (es)
BR (1) BR112017024517A2 (es)
CA (1) CA2985547C (es)
CU (1) CU24487B1 (es)
CY (1) CY1124129T1 (es)
DK (1) DK3294713T5 (es)
EA (1) EA036679B1 (es)
ES (1) ES2868175T3 (es)
HR (1) HRP20210745T1 (es)
HU (1) HUE054009T2 (es)
IL (2) IL255522B (es)
LT (1) LT3294713T (es)
MX (2) MX394388B (es)
MY (1) MY189194A (es)
PH (1) PH12017502052A1 (es)
PL (1) PL3294713T3 (es)
PT (1) PT3294713T (es)
RS (1) RS62016B1 (es)
SI (1) SI3294713T1 (es)
SM (1) SMT202100286T1 (es)
WO (1) WO2016185342A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394388B (es) 2015-05-15 2025-03-21 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
CN109071516B (zh) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 新颖的化合物
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
CN108218845B (zh) * 2016-12-21 2022-11-29 江苏柯菲平医药股份有限公司 一类色满-6-磺酰胺RORγ调节剂及其用途
CN115586652A (zh) 2017-01-23 2023-01-10 奇跃公司 用于虚拟、增强或混合现实系统的目镜
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109111418B (zh) * 2017-06-23 2022-10-11 江苏柯菲平医药股份有限公司 一类2，3-二氢-1H-茚-4-磺酰胺RORγ调节剂及其用途
EP3581565A1 (en) * 2018-06-14 2019-12-18 Beijing Zhibo Bio-Medical Technology Co., Ltd. Phenyl benzyl ether derivative and preparation method and application thereof
CN109232416B (zh) * 2018-10-24 2021-09-24 福州大学 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法
AR117169A1 (es) 2018-11-28 2021-07-14 Bayer Ag (tio)amidas de piridazina como compuestos fungicidas
WO2020127780A1 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Heterocyclyl pyridazine as fungicidal compounds
WO2020172467A1 (en) * 2019-02-20 2020-08-27 The Regents Of The University Of California Treatment for retinoic acid receptor-related orphan receptor ɣ (rorɣ)-dependent cancers
CN109970631A (zh) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 一种5-碘-2-吡啶乙酸的合成方法
WO2021136339A1 (zh) * 2019-12-31 2021-07-08 广东东阳光药业有限公司 具有双环结构的酰胺类化合物及其在药物中的应用
JP7760531B2 (ja) 2020-05-27 2025-10-27 バイエル、アクチエンゲゼルシャフト 活性化合物の組合せ物
WO2021255070A1 (en) 2020-06-18 2021-12-23 Bayer Aktiengesellschaft Active compound combinations
CN112724089B (zh) * 2021-01-05 2022-08-26 烟台皓元生物医药科技有限公司 一种2-氨基-3-溴-6-氯吡嗪的合成工艺
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256340T3 (es) 2000-12-06 2006-07-16 F. Hoffmann-La Roche Ag Activadores heteroaromaticos fusionados de la glucoquinasa.
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
JP4879165B2 (ja) * 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013166013A1 (en) * 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
US9266827B2 (en) * 2012-05-08 2016-02-23 Merck Sharp & Dohme Corp. Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) * 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
EP3027616B1 (en) * 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
EP3041821B1 (en) * 2013-09-05 2018-05-30 Boehringer Ingelheim International GmbH Bicylic compounds as modulators of rorgamma
UA117941C2 (uk) 2013-12-05 2018-10-25 Лід Фарма Холдінг Б.В. МОДУЛЯТОРИ ROR-ГAMMA (RORγ)
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
RS59007B1 (sr) 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
EP3122721A4 (en) 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
WO2015160654A1 (en) 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
MX2016013518A (es) 2014-04-16 2017-01-23 Glenmark Pharmaceuticals Sa Compuestos de aril y heteroaril eter como moduladores de ror gamma.
JP2016034607A (ja) 2014-08-01 2016-03-17 住友電気工業株式会社 水処理システム
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MX394388B (es) 2015-05-15 2025-03-21 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
WO2016193894A1 (en) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
WO2017010399A1 (ja) 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma

Also Published As

Publication number Publication date
MX2017014621A (es) 2018-06-28
EA201792515A1 (ru) 2018-03-30
US20210113551A9 (en) 2021-04-22
JP6982376B2 (ja) 2021-12-17
US20200113892A1 (en) 2020-04-16
MY189194A (en) 2022-01-31
WO2016185342A1 (en) 2016-11-24
EP3294713A4 (en) 2018-10-24
PL3294713T4 (pl) 2021-07-26
PH12017502052A1 (en) 2018-04-30
JP2020117514A (ja) 2020-08-06
AU2021200330B2 (en) 2022-07-28
CN113121497A (zh) 2021-07-16
AU2016262969A1 (en) 2018-01-04
HUE054009T2 (hu) 2021-08-30
JP6684516B2 (ja) 2020-04-22
PT3294713T (pt) 2021-05-24
IL290153A (en) 2022-03-01
KR20180029971A (ko) 2018-03-21
CA2985547A1 (en) 2016-11-24
EP3294713A1 (en) 2018-03-21
CU20170144A7 (es) 2018-04-03
AU2016262969B2 (en) 2020-10-22
EP3294713B1 (en) 2021-02-17
US12377088B2 (en) 2025-08-05
CA2985547C (en) 2024-02-20
US20220125780A1 (en) 2022-04-28
PL3294713T3 (pl) 2021-07-26
MX394388B (es) 2025-03-21
LT3294713T (lt) 2021-06-10
US11229636B2 (en) 2022-01-25
ES2868175T3 (es) 2021-10-21
CU24487B1 (es) 2020-11-30
RS62016B1 (sr) 2021-07-30
AU2021200330A1 (en) 2021-03-18
US20180200247A1 (en) 2018-07-19
HRP20210745T1 (hr) 2021-06-25
HUE054009T4 (hu) 2021-06-28
US20250332155A1 (en) 2025-10-30
AU2016262969C1 (en) 2022-02-24
EA036679B1 (ru) 2020-12-08
NZ738256A (en) 2024-09-27
DK3294713T5 (da) 2021-05-31
HK1255229A1 (zh) 2019-08-09
EP3845526A1 (en) 2021-07-07
CN108026045A (zh) 2018-05-11
SI3294713T1 (sl) 2021-08-31
KR102702236B1 (ko) 2024-09-04
DK3294713T3 (da) 2021-05-10
MX2021009561A (es) 2022-08-01
BR112017024517A2 (pt) 2018-07-24
JP2018515531A (ja) 2018-06-14
SMT202100286T1 (it) 2021-07-12
IL255522A (en) 2018-01-31
CN108026045B (zh) 2021-04-27
CY1124129T1 (el) 2022-05-27
IL255522B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
MX394388B (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
NZ737399A (en) Ccr2 modulators
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
MX2016009013A (es) Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
MX385332B (es) Moduladores de ror-gamma.
EA201491973A1 (ru) Новые соединения
BR112015010649A2 (pt) moduladores de gpr40 à base de pirrolidina
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
MX2016015630A (es) Nuevos compuestos.
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
MX2017006448A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139).
CL2017002799A1 (es) Sulfonas triciclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rory)
MX392163B (es) Moduladores de ror gamma.
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
MX373162B (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas